Although various SGLT2 inhibitors have been shown to have significant protective effects on the kidneys and cardiovascular system in patients with diabetes, recent data has shown that DAPA is also beneficial for those individuals with non-diabetic kidney disease [30]. The gene discussed is SLC5A2; the disease is diabetic kidney disease.